Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Studies of TARCEVA™ (ERLOTINIB HYDROCHLORIDE, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors and in Combination With Irradiation in Newly Diagnosed Brain Stem Glioma

NCT00360854 is registered in ClinicalTrials.gov with Children's Cancer and Leukaemia Group as lead sponsor.

NCT NCT00360854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00360854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Studies of TARCEVA™ (ERLOTINIB HYDROCHLORIDE, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors and in Combination With Irradiation in Newly Diagnosed Brain Stem Glioma
Lead sponsor
Children's Cancer and Leukaemia Group
Phase
Phase 1
Overall status
Unknown status
Start date
May 31, 2005
Completion date
Not reported
Enrollment
48 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors